insights_auto
Why is BAVA up 3,05%?
Dive Deeperchevron_right
BAVA:CPH
Bavarian Nordic A/S
DKK 230,00
arrow_upward
+3,05%(+6,80) 1D
8 Okt., 17:00:00 GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKK 232,20
High
DKK 235,80
Low
DKK 228,40
Mkt. cap
17,62 mjd
Avg. vol.
167,12 k
Volume
368,32 k
52-wk high
DKK 243,70
52-wk low
DKK 171,30
Shares outstanding
79,27 m
No. of employees
2 k
Open
DKK 232,20
High
DKK 235,80
Low
DKK 228,40
Mkt. cap
17,62 mjd
Avg. vol.
167,12 k
Volume
368,32 k
52-wk high
DKK 243,70
52-wk low
DKK 171,30
Shares outstanding
79,27 m
No. of employees
2 k
News stories
From web sources and news partners
The Copenhagen Post
·
6 uur gelede
Bavarian Nordic raises 2026 revenue forecast on stronger travel vaccine sales
MedWatch
·
11 uur gelede
Bavarian Nordic's guidance raise bigger than expected, analyst says
Investing.com
·
12 uur gelede
Why is Bavarian Nordic stock surging today?
Yahoo Finance
·
13 uur gelede
Bavarian Nordic lifts revenue, margin outlook on U.S. rabies vaccine demand
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S